Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 3 Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome

Next Previous
X
Search
Trial Profile

A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 3 Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Mar 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Macitentan (Primary)
  • Indications Down syndrome; Eisenmenger complex
  • Focus Registrational; Therapeutic Use
  • Acronyms MAESTRO
  • Sponsors Actelion Pharmaceuticals

    • Most Recent Events

    • 02 Jan 2019 Results evaluating the efficacy and safety of the endothelin receptor antagonist macitentan in patients with Eisenmenger syndrome, published in the Circulation.
    • 30 Aug 2017 Results of MAESTRO study (n=226) and its haemodynamic substudy (n=39) presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
    • 23 Jan 2017 Results published in an Acetelion Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top